| Company/Division name | Audentes Therapeutics |
| Parent company | Astellas Pharma |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 209 |
| Year reshoring announced: | 2020 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 109.4 |
| Country(ies) from which reshored: | Japan |
| City reshored to: | Sanford |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | gene-therapy |
| What domestic positive factors made reshoring more attractive? | Other, import replacement |
